Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma

Philip, 1987, High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma, N Engl J Med, 316, 1493, 10.1056/NEJM198706113162401 Philip, 1995, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, N Engl J Med, 333, 1540, 10.1056/NEJM199512073332305 Gisselbrecht, 2010, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, J Clin Oncol, 28, 4184, 10.1200/JCO.2010.28.1618 Khouri, 2012, Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results, Blood, 119, 6373, 10.1182/blood-2012-03-417808 Rezvani, 2008, Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience, Br J Haematol, 143, 395, 10.1111/j.1365-2141.2008.07365.x Thomson, 2009, Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma, J Clin Oncol, 27, 426, 10.1200/JCO.2008.17.3328 van Kampen, 2011, Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry, J Clin Oncol, 29, 1342, 10.1200/JCO.2010.30.2596 Kim, 2006, Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan, Blood, 108, 382, 10.1182/blood-2005-02-0596 Armand, 2008, Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome, Biol Blood Marrow Transplant, 14, 418, 10.1016/j.bbmt.2008.01.008 Dhedin, 1999, Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle, Br J Haematol, 107, 154, 10.1046/j.1365-2141.1999.01666.x Bacigalupo, 2009, Defining the intensity of conditioning regimens: working definitions, Biol Blood Marrow Transplant, 15, 1628, 10.1016/j.bbmt.2009.07.004 Weisdorf, 2008, Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival, Biol Blood Marrow Transplant, 14, 748, 10.1016/j.bbmt.2008.04.003 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Shulman, 1980, Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients, Am J Med, 69, 204, 10.1016/0002-9343(80)90380-0 Lazarus, 2010, A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR, Biol Blood Marrow Transplant, 16, 35, 10.1016/j.bbmt.2009.08.011 Clark, 2002, Quantification of the completeness of follow-up, Lancet, 359, 1309, 10.1016/S0140-6736(02)08272-7 Robinson, 2002, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, Blood, 100, 4310, 10.1182/blood-2001-11-0107 Hamadani, 2009, Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas, Biol Blood Marrow Transplant, 15, 547, 10.1016/j.bbmt.2009.01.010 Khouri, 2008, Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab, Blood, 111, 5530, 10.1182/blood-2008-01-136242 Corradini, 2007, Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome, Leukemia, 21, 2316, 10.1038/sj.leu.2404822 Hari, 2008, Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning, Biol Blood Marrow Transplant, 14, 236, 10.1016/j.bbmt.2007.11.004 Vigouroux, 2007, Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC), Haematologica, 92, 627, 10.3324/haematol.10924 Gopal, 2011, 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma, Blood, 118, 1132, 10.1182/blood-2010-12-324392 Bethge, 2010, Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study, Blood, 116, 1795, 10.1182/blood-2010-02-270538 Kenkre, 2011, T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse, Leuk Lymph, 52, 214, 10.3109/10428194.2010.538777 Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403 Vose, 2008, Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index, Biol Blood Marrow Transplant, 14, 36, 10.1016/j.bbmt.2007.06.016 Sirvent, 2010, Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire, Biol Blood Marrow Transplant, 16, 78, 10.1016/j.bbmt.2009.09.002 van Besien, 1997, Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients, Biol Blood Marrow Transplant, 3, 150 Aksentijevich, 2006, Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma, Biol Blood Marrow Transplant, 12, 965, 10.1016/j.bbmt.2006.05.018 Vose, 2001, Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry, J Clin Oncol, 19, 406, 10.1200/JCO.2001.19.2.406 Alousi, 2008, Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation, Br J Haematol, 142, 786, 10.1111/j.1365-2141.2008.07277.x Bacher, 2012, Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?, Blood, 120, 4256, 10.1182/blood-2012-06-436725